AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

Many groups view the skin disease hidradenitis suppurativa (HS) as a new opportunity to expand the reach of their autoimmune blockbusters, particularly since only one novel therapy is approved here.

But that therapy is the now-off-patent Humira, so rivals will have to impress to persuade payers to switch away from Abbvie’s workhorse and its biosimilar versions. And phase 3 data presented at the weekend on both UCB’s Bimzelx and Acelyrin’s izokibep might not quite clear the bar.